Context: Salivary cortisone reflects serum cortisol levels, is more sensitive than salivary cortisol at lower values of serum cortisol and is noninvasive.
| INTRODUCTION
Measurement of salivary cortisol is becoming routine in some clinics for the assessment of adrenal function. Late-night salivary cortisol testing is now recommended as a first-line diagnostic test in Cushing's syndrome, 1 and there are reports of its use in the diagnosis of adrenal insufficiency. [2] [3] [4] [5] [6] [7] [8] [9] [10] Advocates of salivary measurements favour its convenience and potential cost savings over serum sampling. It is noninvasive, painless, has no requirement for clinic attendance and reflects serum-free cortisol, and there is less risk of false-positive results, generated by the cortisol stress response to venipuncture, when testing for Cushing's disease. Recent evidence suggests that salivary cortisone is a better reflection of serum total and free cortisol than salivary cortisol. 2, [11] [12] [13] Serum-free cortisol and salivary cortisol are rapidly oxidized to inactive cortisone, by 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD-2), which is responsible for the large difference in the proportion of salivary cortisol:cortisone (1:6) compared with that in serum (4:1). 11 Salivary cortisone reflects serum cortisol levels both under physiological conditions 2 and after administration of hydrocortisone, with 94% of the variability in salivary cortisone attributable to changes in serum cortisol. 11, 12 Salivary cortisone is more sensitive at low serum cortisol levels than salivary cortisol, making it better suited for the detection of adrenal insufficiency. 2, 5, 8, 12 Stimulation of the adrenal cortex with synthetic (1-24) ACTH (synacthen) is the standard diagnostic test for adrenal insufficiency. 9, 14, 15 The test involves administration of 250 mcg of synacthen, a supraphysiological dose. The low-dose synacthen test (most commonly 1 mcg) is used by some clinicians, as it is thought to more closely mimic a physiological stress stimulus to the adrenal cortex.
14 Results of meta-analyses do not show significant superiority of one test over another, and both doses are used in clinical practice. [16] [17] [18] [19] [20] The measurement of salivary cortisol has been used after stimulation, with different doses of synacthen, in both healthy volunteers and patients. [3] [4] [5] [6] 8, 10 The results support the use of salivary sampling after synacthen, particularly in groups with low serum steroid binding-protein levels and women on estrogens. 10, 12, 21 There are limited data on the use of salivary cortisone following synacthen stimulation. 5, 8, 12 We report the relationship of serum cortisol, salivary cortisol and salivary cortisone following administration of low-and high-dose synacthen and demonstrate the importance of sample timing.
| SUBJECTS AND METHODS
Three prospective pharmacodynamic studies were conducted at the 
| Procedures
The studies were conducted in a similar fashion. All visits commenced and 120 minutes, with replacement of the 15-minute sample with a 2-minute sample in the high-dose study. All blood samples were taken from the indwelling cannula. Saliva sampling was performed using the passive drool technique, which involves volunteers spitting or drooling down a straw into a salicap tube (IBL Hamburg, Germany) for collection. Ten minutes before the first samples were taken, volunteers were asked to rinse their mouth thoroughly with water and did not eat or drink anything (other than water) until conclusion of the study visit.
Saliva sampling was carried out at the same time point as serum sampling with subject initiating the drool at the same time as the syringe was connected to the cannula to withdraw the discard before taking the serum sample. To provide a uniform baseline, all volunteers were dexamethasone suppressed prior to each visit with 1 mg on retiring the night before and a further 1 mg after breakfast on the morning of the test. Successful dexamethasone suppression was established by undetectable ACTH and cortisol at baseline (−1-minute sample).
| Assays
Serum cortisol samples were analysed using the Abbott Architect 
| Statistical analysis
T tests were used to compare the salivary cortisol and salivary cortisone Cmax (peak serum concentration achieved) and Tmax (time at which peak serum concentration achieved) following low-dose synacthen and P < .05 considered significant. A linear mixed-effects model relating the (logarithm of) serum cortisol to each of (logarithm of) salivary cortisol and salivary cortisone was computed. The random effect was taken to be the subject. Pearson correlations were T A B L E 1 Median peak plasma cortisol and salivary cortisol and cortisone concentrations (Cmax) and time to Cmax (Tmax) following administration with low-dose (1 mcg) and high-dose (250 mcg) synacthen 
| RESULTS

| Response to synacthen
Salivary cortisol and cortisone demonstrated similar timeconcentration profiles to serum cortisol following stimulation with high-dose (250 mcg) and low-dose (1 mcg) synacthen (Table 1 and 
| Relationship between serum and salivary observations)
Linearity between variables was achieved after log transformation and both salivary cortisol and cortisone correlated with serum cortisol; however, it was evident that at the early time points, following synacthen, serum cortisol was relatively higher than the salivary measurements ( Figure 2 ). We therefore examined the relationship excluding the samples between baseline and 60 minutes. In this analysis, both salivary cortisol and salivary cortisone showed a close relationship to serum cortisol, with salivary cortisone showing the stronger correlation: salivary cortisol r = .82, P < .001 and salivary cortisone r = .96, P < .001. Our mixed-effects model derived from these data gave the line intercept for (log 10 ) salivary cortisol of 2.17 with a slope of 0.387 and 1.23 for (log 10 ) salivary cortisone with a slope of 0.823. The correlation between the fixed effects prediction for the salivary cortisol model was 0.82, and for the salivary cortisone model, it was 0.96 (P < .001).
We further examined the relationship between salivary cortisone and serum cortisol at each individual time point (Figure 3 ). From these data, it can be seen that, after the baseline sample and up to 30 minutes, the value of serum cortisol falls above the regression line for the fixed effects model. At 40 minutes, the serum cortisol is closer, but the majority of values lie above the regression line, and from 50 to 120 minutes, the serum cortisol falls on or near the regression line. we can see that at time zero, there is a very poor correlation for salivary cortisol (r = .45, NS) because many samples fall below the lower limit of detection, but for salivary cortisone, there was a strong correlation (r = .94, P < .001). After synacthen, the correlation between serum cortisol and salivary cortisol and salivary cortisone fell and then rose so that after 50 minutes, the correlation was r > .8, P < .001 for both.
| DISCUSSION
Our results show that following synacthen, salivary cortisone reflects serum cortisol levels, but importantly there was a lag in the rise in salivary cortisone such that up to 50 minutes, salivary cortisone was lower than would be predicted from serum cortisol values. Salivary cortisone showed a stronger correlation with serum cortisol than salivary cortisol primarily because at low levels of serum cortisol, salivary cortisol was <0.8 nmol/L. The results support the use of salivary cortisone measurement during the synacthen test but suggest that rather than using a 30-minute sample, as is commonly used with serum cortisol, the measurement of salivary cortisone at 60 minutes may be a more reliable reflection in serum cortisol.
The response of serum cortisol to both 250 and 1 mcg synacthen is consistent with previous reports and thus demonstrates a reliable and reproducible response. [23] [24] [25] Exposure to two doses of dexamethasone would not be expected to suppress the adrenal gland but reduces the basal cortisol level and therefore the peak serum cortisol achieved by our healthy subjects. Even with a modest early morning baseline of 4 mcg/dL (110 nmol/L), all subjects would have reached a peak cortisol of more than 18 mcg/dL (500 nmol/L) at 60 minutes and more than 16 mcg/dL (450 nmol/L) at 30 minutes (our local assay-derived diagnostic threshold). 
12
The challenges of obtaining accurately paired salivary and blood samples, performed at very close intervals in order to model the pharmacodynamics of the response to synacthen, may also give rise to a reduced correlation, most obvious during the early frequent sampling times.
The mixed-effects model for serum cortisol and salivary cortisone applied to our data is similar to that previously published. 11 The line intercepts are the same (our data 1.23, published model 1.24), but slopes differ by a small degree (our data 0.823, published model 0.981, P < .001). 11 The difference may reflect the different assay techniques employed to quantify serum cortisol. 27 The published model used LC/ MS-MS, whereas in this study we used an immunoassay.
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The limitations of this study include the following: (i) the study was carried out on healthy individuals; (ii) that dexamethasone administration may interfere with the interpretation of the test; (iii) broadbased assay and test validation is necessary prior to introducing this methodology into clinical practice; (iv) our study used measurement of serum cortisol by immunoassay rather than LC-MS/MS; and (v) we did not measure serum levels of free cortisol or cortisone. However, our results relating the serum with salivary measurements fit with the F I G U R E 4 A, Correlation coefficients of serum cortisol and salivary cortisol at each time point following synacthen administration (correlation coefficients for −1-, 5-and 10-min samples not significant). B, Correlation coefficients of serum cortisol and salivary cortisone at each time point following synacthen administration previous literature, and the strong correlation between free serum cortisol and salivary cortisol has been extensively reported, 11, 12 as has the lack of rise of serum-free cortisone following synacthen. 12 The use of healthy volunteers has the advantage of a very tightly controlled study with a uniform population of subjects. Further work is required to demonstrate whether similar responses are seen using different assay platforms, in non-dexamethasone-suppressed individuals and those with adrenocortical insufficiency.
Our results indicate that salivary cortisone reflects the serum cortisol response to synacthen but suggest that a 60-minute sample would be best used for diagnostic accuracy. However, before advocating replacement of a serum-based cortisol assay for cortisol quantification following synacthen administration, further studies are required in patient populations, without dexamethasone suppression and using LC-MS/MS to confirm our findings and define normal ranges of salivary cortisone and the diagnostic cut-offs for adrenal insufficiency.
